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Abstract
Background: Probiotics are increasingly used in the treatment of functional gastrointestinal disorders. Studies in
constipated adults with a Bifidus yoghurt (containing Bifidobacterium breve, Bifidobacterium bifidum and
Lactobacillus acidophilus) showed a significant increase in defecation frequency. The aim of this pilot study was to
determine if Bifidobacterium breve is effective in the treatment of childhood constipation.
Methods: Children, 3 to 16 years of age, with functional constipation according to the Rome III criteria were
eligible for this study. During 4 weeks, children received one sachet of powder daily, containing 108- 1010 CFU
Bifidobacterium breve. Furthermore, children were instructed to try to defecate on the toilet for 5-10 minutes after
each meal and to complete a standardized bowel diary daily. The primary outcome measure was change in
defecation frequency. Secondary outcome measures were stool consistency using the Bristol stool scale frequency
of episodes of faecal incontinence, pain during defecation, frequency of abdominal pain, frequency of adverse
effects (nausea, diarrhoea and bad taste), and frequency of intake of bisacodyl.
Results: Twenty children (75% male, mean age 7.4) were included in this pilot study. The defecation frequency per
week significantly increased from 0.9 (0-2) at baseline to 4.9 (0-21) in week 4 (p < 0.01). The mean stool
consistency score increased from 2.6 (2-4) at baseline to 3.5 (1-6) in week 4 (p = 0.03). The number of faecal
incontinence episodes per week significantly decreased from 9.0 (0-35) at baseline to 1.5 (0-7) in week 4 (p < 0.01).
Abdominal pain episodes per week significantly decreased from 4.2 (0-7) at baseline to 1.9 (0-7) in week 4 (p =
0.01). No side effects occurred.
Conclusion: Bifidobacterium breve is effective in increasing stool frequency in children with functional constipation.
Furthermore it has a positive effect with respect to stool consistency, decreasing the number of faecal
incontinence episodes and in diminishing abdominal pain. A randomized placebo controlled trial is required to
confirm these data.
Background
Functional constipation is a common and frustrating
problem in childhood with an estimated prevalence of
3% in the western world [1]. This chronic condition is
characterised by infrequent defecation less than three
times per week, more than two episodes of faecal incon-
tinence per week, the passage of large and painful stools
which clog the toilet and retentive posturing. Upon phy-
sical examination a palpable faecal mass is often found
in the abdomen and the rectum [2,3]. It causes distress
to child and family and results in severe emotional dis-
turbance and family discord [4]. The pathophysiology
underlying functional constipation is undoubtedly multi-
factorial, and not well understood. Withholding beha-
viour is probably the major cause for the development
of constipation and might be caused by the previous
production of a large, hard painful stool, anal fissures, a
primarily behavioural mechanism or the resistance to go
to another toilet then their own [4].
To date, patients are treated with a combination of
education, toilet training and oral laxatives. Disappoint-
ingly, only 50% of all children followed for 6 to
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12 months are found to recover and were successfully
taken off laxatives [5]. Another study showed that
despite intensive medical and behavioural therapy, 25%
of patients developing constipation before the age of
5 years continued to have severe complaints of constipa-
tion beyond puberty [6]. Furthermore, in 50% of the
patients using these compounds, adverse side-effects
were registered such as: abdominal pain, bloating,
flatulence, diarrhoea, nausea and bad taste [7]. No data
exist concerning possible long-term adverse effects such
as electrolyte disturbances, mucosal damage and
habituation.
Probiotics are defined as live micro-organisms which
when administered in adequate amounts, 106-109 colony
forming units, confer a health benefit on the host [8].
The use of probiotics has entered mainstream medicine
and has proven being an effective therapy in many dif-
ferent gastrointestinal disorders, including functional
gastrointestinal disorders [9,10]. However, large trials
investigating the efficacy and safety of probiotics
in pediatric patients are lacking [11,12]. Studies in
constipated adults with a Bifidus yoghurt, containing
Bifidobacterium breve, Bifidobacterium bifidum and Lac-
tobacillus acidophilus, showed a significant increase in
defecation frequency without any side effects [13,14].
Furthermore, a randomized controlled trial using Bifido-
bacterium breve in preterm infants showed less gas
accumulation in the stomach, less vomiting and
improved weight gain without any side effects, suggest-
ing a positive effect on gastrointestinal motility [15] The
exact working mechanism of probiotics are not well
understood. There are some hypotheses, however, why
probiotics might have therapeutic potential for the treat-
ment of constipation. Firstly, a dysbiosis in the gut flora
in constipated patients has been suggested which might
improve after the ingestion of probiotics [9,10]. It
remains important however to understand if dysbiosis is
a secondary manifestation of constipation, or if it is a
factor contributing to constipation. Furthermore, pro-
biotics can lower pH of the colon by producing lactic,
acetic and other short chain fatty acids. A lower pH
enhances colonic peristalsis and subsequently decreases
colonic transit time [9,10].
Based on the positive data in constipated adults, we
therefore performed a pilot study to determine if Bifido-




Children, 3 to 16 years of age, referred to the outpatient
clinic of a tertiary pediatric gastroenterology depart-
ment, with constipation were eligible for this study.
Patients were included if they had been suffering from
functional constipation according to the Rome III cri-
teria for the last 2 months [2,3]. All children included
had a defecation frequency of <3 times/week and one or
more of the following criteria: faecal incontinence >1 epi-
sode/week, a large amount of stools that clog the toilet,
painful defecation, withholding behaviour, or abdominal
or rectal faecal impaction upon physical examination. In
order to obtain a homogeneous group of patients, we
included children with a defecation frequency <3 times/
week in combination with at least one other ROME III
criterion. Patients were not enrolled in this study if they
had been treated for constipation less than 2 weeks
before the start of the study. Other exclusion criteria
were: a diagnosis of either IBS or functional non-
retentive faecal incontinence according to the Rome III
criteria; a diagnosis of mental retardation or metabolic
disease (hypothyroidism), Hirschsprung’s disease, spinal
anomalies, anorectal pathology, previous gastrointestinal
surgery. All children older than 12 years and/or parents
gave informed consent. This pilot was approved by the
medical ethical committee,
Study design
Seven days prior to baseline assessment and during the
treatment period, all children recorded frequency of
bowel movements, stool consistency according to the
Bristol stool scale, the number of faecal incontinence
episodes, pain during defecation, abdominal pain, as
well as adverse effects such as vomiting and diarrhoea
in a standardized bowel diary. At baseline a medical his-
tory and information on the current defection pattern
was collected and also a physical examination including
a rectal digital exam was performed. Information and
education about functional constipation was given to all
patients and their care takers. Before start of the probio-
tic treatment, all children received once daily for 3 days
a rectal enema in order to accomplish rectal disimpac-
tion. After rectal disimpaction, all children received
daily one sachet of powder containing 108-10 CFU Bifi-
dobacterium breve Yakult, for 4 weeks. The patients
were allowed to mix the powder with all liquids on con-
dition that the liquid was not hot. During the study, all
children were instructed to try to defecate on the toilet
for 5-10 minutes after each meal (3 times a day).
Patients were not allowed to consume any other fer-
mented dairy product during this study or any other
laxatives, except for the rescue medication Biscaodyl.
Names of the forbidden products were pointed out in
the diary. During the product consumption period,
patients were instructed to take bisacodyl 5 mg if they
did not defecate for 3 consecutive days. Clinical evalua-
tion, frequency of adverse effects and compliance to the
study protocol were carried out at enrolment and at 2, 4
and 6 weeks using standardized bowel diaries.
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Outcome measures
The primary outcome measure was change in defecation
frequency in week 4 compared to baseline. Secondary
outcome measures were stool consistency, frequency of
episodes of faecal incontinence, pain during defecation,
frequency of abdominal pain, frequency of adverse
effects (nausea, diarrhoea and bad taste), and frequency
of intake of bisacodyl.
Analysis
Descriptive statistics were performed for baseline char-
acteristics, adverse effects and Bisacodyl use. Change of
frequency of bowel movements, fecal incontinence and
change of stool consistency, was assessed using the non-
parametric paired Wilcoxon test. For the comparison of
abdominal pain between baseline and the evaluation
time points, the Wilcoxon rank test was used. A p-value
< 0.05 was considered to be significant. All analyses
were done with SPSS (version 16.0).
Results
Between July 2009 and January 2010, 22 children were
included into this pilot study. Two children were lost to
follow-up without having any outcome data during fol-
low-up. Both patients were therefore excluded from the
final analysis. All outcomes of the remaining 20 children
were collected and analyzed. The baseline characteristics
are described in Table 1 (mean (range))
The defecation frequency per week significantly
increased from 0.9 (0-2) at baseline to 5.3 (0-21) in week
2 (p < 0.01) and 4.9 (0-21) in week 4 (p < 0.01) (figure 1:
Defecation frequency over 4 weeks.). The mean stool
consistency score significantly increased from 2.6 (2-4) at
baseline to 3.6 (1-6) in week 2 (p = 0.07) and 3.5 (1-6) in
week 4 (p = 0.03). The episodes of faecal incontinence
per week significantly decreased from 9.0 (0-35) at base-
line to 2.6 (0-7) in week 2 (p = 0.01) and 1.5 (0-7) in
week 4 (p < 0.01). Pain during defecation decreased from
71% (12/17) at baseline to 40% (8/20) in week 2 (p =
0.10) and 33% (6/18) in week 4 (p = 0.08). Abdominal
pain episodes per week significantly decreased from 4.2
(0-7) at baseline to 2.2 (0-7) in week 2 (p = 0.02) and 1.9
(0-7) in week 4 (p = 0.01). Bisacodyl was used by 45% of
patients during week 1, 25% of patients during week 2,
35% of patients during week 3 and by 20% of patients
during week 4. No side effects were reported such as
nausea, diarrhoea and bad taste or increased flatulence
during the study period. Table 2 gives an overview of the
outcome measures with p-values.
Discussion
This pilot study showed that intake of Bifidobacterium
breve for 4 weeks, significantly increased the defecation
frequency. Furthermore, stool consistency, the frequency
of episodes of faecal incontinence and the frequency of
abdominal pain significantly changed after the use of
this specific probiotic strain.
A recent systematic review on the effects of laxative
treatment and dietary measures in the management of
childhood constipation found only 2 randomized con-
trolled trials evaluating the effects of probiotics [16]. In the
first small study, 45 children younger than 10 years with
chronic constipation were randomly assigned to receive
magnesium oxide (50 mg/kg/day (n = 18), or 8 × 108 cfu/
day of the probiotic Lactobacillus casei rhamnosus (n =
18), or placebo (n = 9) twice daily for 4 weeks [17]. No sta-
tistically significant difference in the defecation frequency
per day was found between the probiotic group and the
magnesium oxide group. However, patients receiving
either the probiotic strain or the oral laxative had a signifi-
cantly higher defecation frequency compared to the pla-
cebo group (defecation frequency [times/day 0.57 ± 0.17
and 0.55 ± 0.13, respectively, compared to 0.37 ± 0.10, p =
0.03). The second trial was conducted to determine if Lac-
tobacillus rhamnosus GG (LGG) is an effective adjunct to
lactulose for treating constipation in children. A total of
48 children with constipation received 1 ml/kg/day of 70%
lactulose plus 109 cfu of LGG or 1 ml/kg/day of 70% lactu-
lose plus placebo, twice daily for 12 weeks [12]. There
were no significant differences in rates of product success
(defined as ≥ 3 spontaneous stools per week with no faecal
incontinence) at 12 and 24 weeks between the LGG group
(rates: 72% and 64%, respectively) and the placebo group
(rates: 68% and 65%, respectively). `
In a recent trial, 44 children, at least 6 months old,
with chronic constipation were randomly assigned to
receive supplementation with the probiotic Lactobacillus
reuteri (DSM 17938) (n = 22) or placebo (n = 22) [18].
Infants receiving Lactobacillus reuteri had a significantly
higher frequency of bowel movements than infants
receiving a placebo at week 8 of supplementation (2.82
per week at week 0, compared with 4.77 at week 8 in
the probiotic group, absolute numbers not given for pla-
cebo group, P = 0.027). There was no significant differ-
ence between Lactobacillus reuteri and placebo groups
in the stool consistency at all weeks nor in the presence
of inconsolable crying episodes. All three trials did not
report any adverse events in the probiotic group.
Table 1 Baseline patient characteristics: mean (range)
Age in years 7.4 (4-13)
Boys, n (%) 15 (75%)
Mean stool frequency per week 0.9 (0-2)
Stool consistency score 2.6 (2-4)
Faecal incontinence episodes per week 9 (0-35)
Pain during defecation 71% (12/17)
Abdominal pain episodes per week 4.2 (0-7)
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A mixture of probiotics (containing Bifidobacteria (B.)
bifidum, B. infantis, B. longum, Lactobacillus (L.) casei,
L. plantarum and L. rhamnosus), increased the number
of bowel movements, decreased the number of faecal
incontinence episodes and improved the consistency of
stools [19]. Although the results of this small pilot study
are positive, a large randomized controlled trial is neces-
sary to confirm these data.
It is unknown why the outcome of the above men-
tioned trials in constipated children is so different. We
speculate that the use of different inclusion criteria for
paediatric constipation with consequently different study
populations and the use of different probiotic strains,
given in different dosages with variable duration of the
treatment period, influence study outcomes.
In contrast to the few paediatric studies, data suggest
that adults with constipation might benefit from inges-
tion of B. lactis DN-173 010, L. casei Shirota, and E. coli
Nissle 1917. All studies showed an increased defecation
frequency and improved stool consistency [20]. These
findings, however are not directly applicable to the pae-
diatric population because constipation in children dif-
fers considerably from that in constipated adults with
regard to its prevalence, onset, aetiology, symptoms,
treatment, and prognosis [21].
Besides the increase in defecation frequency and
decrease in episodes of faecal incontinence, this study
also showed a significant effect in softening of stools
and in decreasing abdominal pain. Both effects could be
a direct consequence an increase in defecation but theo-
retically, it could also be caused by the working
mechanism of the probiotics. It has been assumed that
probiotics soften the stools by stimulating water and
electrolyte secretion [22,23]. Furthermore, one paediatric
study and several studies in adults with irritable bowel
syndrome (IBS), have demonstrated that abdominal pain
Figure 1 Primary outcome: change in defecation frequency (n = 20). X-axis: week number. Y-axis: defecation frequency per week.
Table 2 Main outcome measures (mean) with p-values (n = 20)
Outcome At baseline Week 2 Week 4 P-value (week 4-week 0)
Defecation frequency p/week 0.9 5.3 4.9 p < 0.01
Stool consistency score 2.6 3.6 3.5 p = 0.03
Episodes of faecal incontinence p/week 9.0 2.6 1.5 p < 0.01
Pain during defecation 71% 40% 33% p = 0.08
Abdominal pain episodes p/week 4.2 2.2 1.9 p = 0.01
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decreased when using probiotics [17,24,25]. Whorwell
et al. conducted a randomized trial in 360 women with
IBS receiving Bifidobacterium infantis and found a signif-
icant improvement of abdominal pain which occurred
irrespective of any effect on stool frequency. The authors
hypothesized that the probiotics were able to diminish
visceral hypersensitivity by its anti-inflammatory effect
on the enteric mucosa [26].
According to the available data, it is assumed that the
risk of infection with the probiotic lactobacilli or bifido-
bacteria is similar to risks with commensal strains [10].
However, there is concern that the use of probiotics may
result in harmful events in at-risk populations like immu-
nocompromized subjects or in patients with other life-
threatening illnesses, who were admitted in the intensive
care unit. Based on our results and their safety profile,
adding probiotics to the standard treatment of functional
constipation in otherwise healthy children is promising.
The major limitation of our study is that this study is a
non randomized non placebo controlled small pilot
study. However, since this study shows promising results
it is worthwhile to perform a large RCT to unravel the
efficacy of Bifidobacterium breve in constipated children.
In conclusion, this small pilot study suggests that Bifido-
bacterium breve is effective in the treatment of childhood
constipation. A large randomized placebo controlled trial
is now required to confirm these data.
Acknowledgements
The authors wish to thank the Yakult Central Institute for Microbiological
Research, Tokyo, Japan for the supply of product. Yakult Netherlands BV,
Amstelveen, The Netherlands has funded this study.
Authors’ contributions
MMT and MAB participated in the design of the study.
All authors collected the data.
MMT and IDM did the statistical analysis.
MMT drafted the first manuscript.
All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 13 August 2010 Accepted: 23 February 2011
Published: 23 February 2011
References
1. van den Berg MM, Benninga MA, Di LC: Epidemiology of childhood
constipation: a systematic review. Am J Gastroenterol 2006, 101:2401-2409.
2. Hyman PE, Milla PJ, Benninga MA, Davidson GP, Fleisher DF, Taminiau J:
Childhood functional gastrointestinal disorders: neonate/toddler.
Gastroenterology 2006, 130:1519-1526.
3. Rasquin A, Di LC, Forbes D, Guiraldes E, Hyams JS, Staiano A, et al:
Childhood functional gastrointestinal disorders: child/adolescent.
Gastroenterology 2006, 130:1527-1537.
4. Benninga MA, Voskuijl WP, Taminiau JA: Childhood constipation: is
there new light in the tunnel? J Pediatr Gastroenterol Nutr 2004,
39:448-464.
5. Pijpers MA, Bongers ME, Benninga MA, Berger MY: Functional constipation
in children: a systematic review on prognosis and predictive factors.
J Pediatr Gastroenterol Nutr 2010, 50:256-268.
6. Bongers ME, van Wijk MP, Reitsma JB, Benninga MA: Long-term prognosis
for childhood constipation: clinical outcomes in adulthood. Pediatrics
2010, 126:e156-e162.
7. Voskuijl W, de LF, Verwijs W, Hogeman P, Heijmans J, Makel W, et al: PEG
3350 (Transipeg) versus lactulose in the treatment of childhood
functional constipation: a double blind, randomised, controlled,
multicentre trial. Gut 2004, 53:1590-1594.
8. Gill HS, Guarner F: Probiotics and human health: a clinical perspective.
Postgrad Med J 2004, 80:516-526.
9. Picard C, Fioramonti J, Francois A, Robinson T, Neant F, Matuchansky C:
Review article: bifidobacteria as probiotic agents – physiological effects
and clinical benefits. Aliment Pharmacol Ther 2005, 22:495-512.
10. Szajewska H, Setty M, Mrukowicz J, Guandalini S: Probiotics in
gastrointestinal diseases in children: hard and not-so-hard evidence of
efficacy. J Pediatr Gastroenterol Nutr 2006, 42:454-475.
11. Chmielewska A, Szajewska H: Systematic review of randomised controlled
trials: probiotics for functional constipation. World J Gastroenterol 2010,
16:69-75.
12. Banaszkiewicz A, Szajewska H: Ineffectiveness of Lactobacillus GG as an
adjunct to lactulose for the treatment of constipation in children: a
double-blind, placebo-controlled randomized trial. J Pediatr 2005,
146:364-369.
13. Tanaka R, Shimosaka K: Investigation of the stool frequency in elderly
who are bed ridden and its improvements by ingesting bifidus yogurt.
Nippon Ronen Igakkai Zasshi 1982, 19:577-582.
14. Matsui T, Iida K, Okumura T, Hatano M: Effect of Bifidus yogurt on the
defecation frequency of the elderly. Jpn J Nutrition 2000, 58:213-218.
15. Kitajima H, Sumida Y, Tanaka R, Yuki N, Takayama H, Fujimura M: Early
administration of Bifidobacterium breve to preterm infants: randomised
controlled trial. Arch Dis Child Fetal Neonatal Ed 1997, 76:F101-F107.
16. Pijpers MA, Tabbers MM, Benninga MA, Berger MY: Currently
recommended treatments of childhood constipation are not evidence
based: a systematic literature review on the effect of laxative treatment
and dietary measures. Arch Dis Child 2009, 94:117-131.
17. Bu LN, Chang MH, Ni YH, Chen HL, Cheng CC: Lactobacillus casei
rhamnosus Lcr35 in children with chronic constipation. Pediatr Int 2007,
49:485-490.
18. Coccorullo P, Strisciuglio C, Martinelli M, Miele E, Greco L, Staiano A:
Lactobacillus reuteri (DSM 17938) in Infants with Functional Chronic
Constipation: A Double-Blind, Randomized, Placebo-Controlled Study.
J Pediatr 2010, 157:598-602.
19. Bekkali NL, Bongers ME, van den Berg MM, Liem O, Benninga MA: The role
of a probiotics mixture in the treatment of childhood constipation:
a pilot study. Nutr J 2007, 6:17.
20. Chmielewska A, Szajewska H: Systematic review of randomised controlled
trials: probiotics for functional constipation. World J Gastroenterol 2010,
16:69-75.
21. Solzi G, Di LC: Are constipated children different from constipated
adults? Dig Dis 1999, 17:308-315.
22. Moro G, Minoli I, Mosca M, Fanaro S, Jelinek J, Stahl B, et al: Dosage-related
bifidogenic effects of galacto- and fructooligosaccharides in formula-fed
term infants. J Pediatr Gastroenterol Nutr 2002, 34:291-295.
23. Bongers ME, de LF, Reitsma JB, Groeneweg M, Taminiau JA, Benninga MA:
The clinical effect of a new infant formula in term infants with
constipation: a double-blind, randomized cross-over trial. Nutr J 2007, 6:8.
24. Niedzielin K, Kordecki H, Birkenfeld B: A controlled, double-blind,
randomized study on the efficacy of Lactobacillus plantarum 299 V in
patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol 2001,
13:1143-1147.
25. Whorwell PJ, Altringer L, Morel J, Bond Y, Charbonneau D, O’Mahony L,
et al: Efficacy of an encapsulated probiotic Bifidobacterium infantis
35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006,
101:1581-1590.
26. McCarthy J, O’Mahony L, O’Callaghan L, Sheil B, Vaughan EE, Fitzsimons N,
et al: Double blind, placebo controlled trial of two probiotic strains in
interleukin 10 knockout mice and mechanistic link with cytokine
balance. Gut 2003, 52:975-980.
doi:10.1186/1475-2891-10-19
Cite this article as: Tabbers et al.: Is Bifidobacterium breve effective in
the treatment of childhood constipation? Results from a pilot study.
Nutrition Journal 2011 10:19.
Tabbers et al. Nutrition Journal 2011, 10:19
http://www.nutritionj.com/content/10/1/19
Page 5 of 5
